Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Echo Therapeutics, a developer of transdermal diagnostic devices and specialty pharmaceuticals, has received a new US patent which covers compositions and methods for the preparation of a polyethylene glycol-based hydrogel as a key component of the company's Symphony transdermal continuous glucose monitoring system.
Subscribe to our email newsletter
Echo’s Symphony transdermal continuous glucose monitoring (tCGM) system is in late-stage development for both the diabetes home use and hospital critical care settings. Symphony incorporates Echo’s new Prelude SkinPrep system with patented, skin permeation control technologies.
Patrick Mooney, chairman and CEO of Echo Therapeutics, said: “Our proprietary polyethylene glycol hydrogel, specifically designed to enable transdermal biosensing, is characterized by excellent stability, sensitivity, integrity and biocompatibility, making our Symphony tCGM system a desirable system for non-invasive continuous glucose monitoring.
“This patent is critical to our intellectual property strategy for protecting our leading position in non-invasive, tCGM markets worldwide.”